Medical oncologists share expert perspectives on treatment paradigms for patients with early-stage NSCLC and actionable mutations.
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
Alectinib shows promising long-term survival benefits over crizotinib for advanced ALK-positive NSCLC, highlighting significant clinical advancements.
Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.
Zongertinib Maintains Efficacy Benefit in First-line HER2-Mutated NSCLC
Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting
Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Sunvozertinib Exhibits Favorable Responses in EGFR-Mutated NSCLC
Treatment-related AEs with sunvozertinib were consistent with EGFR tyrosine kinase inhibitors in patients with NSCLC with EGFR exon 20 insertion mutations.
Radiation Shows Similar 10-Year Outcomes Vs Surgery in Early-Stage NSCLC
Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.